vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Pangaea Logistics Solutions Ltd. (PANL). Click either name above to swap in a different company.
Pangaea Logistics Solutions Ltd. is the larger business by last-quarter revenue ($183.9M vs $183.1M, roughly 1.0× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.5%, a 6.9% gap on every dollar of revenue. On growth, Pangaea Logistics Solutions Ltd. posted the faster year-over-year revenue change (24.9% vs -1.8%). Over the past eight quarters, Pangaea Logistics Solutions Ltd.'s revenue compounded faster (32.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Pangaea Logistics Solutions Ltd. is a global dry bulk logistics and shipping service provider. It operates a modern fleet of dry bulk vessels to transport a wide range of commodities including grains, minerals, construction materials, and energy-related raw materials, serving industrial, agricultural, and energy sector clients across North America, Europe, and Asia with tailored end-to-end bulk cargo supply chain solutions.
AMPH vs PANL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $183.9M |
| Net Profit | $24.4M | $11.9M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 9.5% |
| Net Margin | 13.3% | 6.5% |
| Revenue YoY | -1.8% | 24.9% |
| Net Profit YoY | -35.7% | 40.9% |
| EPS (diluted) | $0.51 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $183.9M | ||
| Q3 25 | $191.8M | $168.7M | ||
| Q2 25 | $174.4M | $156.7M | ||
| Q1 25 | $170.5M | $122.8M | ||
| Q4 24 | $186.5M | $147.2M | ||
| Q3 24 | $191.2M | $153.1M | ||
| Q2 24 | $182.4M | $131.5M | ||
| Q1 24 | $171.8M | $104.7M |
| Q4 25 | $24.4M | $11.9M | ||
| Q3 25 | $17.4M | $12.2M | ||
| Q2 25 | $31.0M | $-2.7M | ||
| Q1 25 | $25.3M | $-2.0M | ||
| Q4 24 | $38.0M | $8.4M | ||
| Q3 24 | $40.4M | $5.1M | ||
| Q2 24 | $37.9M | $3.7M | ||
| Q1 24 | $43.2M | $11.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 9.5% | ||
| Q3 25 | 13.2% | 10.0% | ||
| Q2 25 | 24.2% | 2.3% | ||
| Q1 25 | 21.9% | 2.4% | ||
| Q4 24 | 24.2% | 10.1% | ||
| Q3 24 | 29.8% | 9.8% | ||
| Q2 24 | 30.3% | 5.8% | ||
| Q1 24 | 27.9% | 10.5% |
| Q4 25 | 13.3% | 6.5% | ||
| Q3 25 | 9.0% | 7.2% | ||
| Q2 25 | 17.8% | -1.8% | ||
| Q1 25 | 14.8% | -1.6% | ||
| Q4 24 | 20.4% | 5.7% | ||
| Q3 24 | 21.1% | 3.3% | ||
| Q2 24 | 20.8% | 2.8% | ||
| Q1 24 | 25.1% | 11.1% |
| Q4 25 | $0.51 | $0.18 | ||
| Q3 25 | $0.37 | $0.19 | ||
| Q2 25 | $0.64 | $-0.04 | ||
| Q1 25 | $0.51 | $-0.03 | ||
| Q4 24 | $0.74 | $0.19 | ||
| Q3 24 | $0.78 | $0.11 | ||
| Q2 24 | $0.73 | $0.08 | ||
| Q1 24 | $0.81 | $0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $103.1M |
| Total DebtLower is stronger | $608.7M | $249.6M |
| Stockholders' EquityBook value | $788.8M | $429.3M |
| Total Assets | $1.6B | $928.1M |
| Debt / EquityLower = less leverage | 0.77× | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $103.1M | ||
| Q3 25 | $276.2M | $94.0M | ||
| Q2 25 | $231.8M | $59.3M | ||
| Q1 25 | $236.9M | $63.9M | ||
| Q4 24 | $221.6M | $86.8M | ||
| Q3 24 | $250.5M | $93.1M | ||
| Q2 24 | $217.8M | $77.9M | ||
| Q1 24 | $289.6M | $95.9M |
| Q4 25 | $608.7M | $249.6M | ||
| Q3 25 | $608.6M | $256.2M | ||
| Q2 25 | $607.7M | $244.7M | ||
| Q1 25 | $603.9M | $251.0M | ||
| Q4 24 | $601.6M | $257.2M | ||
| Q3 24 | $596.4M | $133.6M | ||
| Q2 24 | $586.9M | $90.5M | ||
| Q1 24 | $594.0M | $95.9M |
| Q4 25 | $788.8M | $429.3M | ||
| Q3 25 | $776.7M | $420.3M | ||
| Q2 25 | $757.5M | $414.4M | ||
| Q1 25 | $751.3M | $420.8M | ||
| Q4 24 | $732.3M | $427.8M | ||
| Q3 24 | $727.7M | $332.6M | ||
| Q2 24 | $713.3M | $331.5M | ||
| Q1 24 | $672.4M | $332.0M |
| Q4 25 | $1.6B | $928.1M | ||
| Q3 25 | $1.7B | $932.1M | ||
| Q2 25 | $1.6B | $916.0M | ||
| Q1 25 | $1.6B | $918.0M | ||
| Q4 24 | $1.6B | $936.5M | ||
| Q3 24 | $1.5B | $749.2M | ||
| Q2 24 | $1.5B | $692.9M | ||
| Q1 24 | $1.6B | $703.3M |
| Q4 25 | 0.77× | 0.58× | ||
| Q3 25 | 0.78× | 0.61× | ||
| Q2 25 | 0.80× | 0.59× | ||
| Q1 25 | 0.80× | 0.60× | ||
| Q4 24 | 0.82× | 0.60× | ||
| Q3 24 | 0.82× | 0.40× | ||
| Q2 24 | 0.82× | 0.27× | ||
| Q1 24 | 0.88× | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $15.1M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 1.27× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $15.1M | ||
| Q3 25 | $52.6M | $28.6M | ||
| Q2 25 | $35.6M | $14.4M | ||
| Q1 25 | $35.1M | $-4.4M | ||
| Q4 24 | $29.0M | $19.3M | ||
| Q3 24 | $60.0M | $28.5M | ||
| Q2 24 | $69.1M | $9.0M | ||
| Q1 24 | $55.3M | $9.0M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | 1.27× | ||
| Q3 25 | 3.03× | 2.34× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 2.29× | ||
| Q3 24 | 1.48× | 5.57× | ||
| Q2 24 | 1.82× | 2.43× | ||
| Q1 24 | 1.28× | 0.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PANL
| Voyage | $166.3M | 90% |
| Charter | $13.1M | 7% |
| Terminal Stevedore Revenue | $4.4M | 2% |
